CSI Market
Sign In | Register

Sigyn Therapeutics Inc (RSAP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access RSAP Annual Cash Flow →
The table below presents a historical view of Sigyn Therapeutics Inc's cash flow activity, supporting analysis of liquidity trends over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2025)
9 Months 		(Jun 30 2025) (Mar 31 2025) (Dec 31 2024) (Sep 30 2024)
Operating Activities
Income-2.70
Depreciation & amortization0.00
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.15
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.02
Stock Based Compensation Related Party-
Interest Expense In Conjunction With Debt Issuance-
Accretion Of Discount-
Standardized Measure Of Discounted Future Net Cash Flow Relating To Proved Oil And Gas Reserves Accretion Of Discount-
Fair Value Adjustment Of Warrants-
Accretion Of Debt Discount0.14
Change In Derivative Liabilities-
Increase Decrease In Accrued Compensation Related Party-
Amortization Of Stock Issued For Future Services-
Inducement Of Preferred Shares0.85
Settlement Of Lease-0.01
Increase Decrease In Other Assets0.02
Income taxes0.41
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.17
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.00
Other Working Capital0.01
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.30
Discontinued operations0.00
Net Cash flow from Operating Activities-0.65
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Sales of Business, Affiliate and Productive Assets0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.71
Other borrowing transactions0.00
Long-term debt - borrowings0.01
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Repayments Of Short Term Notes Related Party-
Proceeds From Shortterm Notes Related Party-
Common Stock Issued For Cash-
Proceeds From Issuance Of Common Stock And Warrants Issued For Cash-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.72
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.65
Total Cash Flow0.07
4 historic quarters locked

Sign in to unlock the full Sigyn Therapeutics Inc cash flow history.

Sign In Create Free Account

About Sigyn Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20250930)
  • Filed with the SEC: November 14, 2025
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-25-023387

Figures are derived from filed reports and may be restated. Historical data is subject to revision.